ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $12.50.

A number of research firms have commented on ALXO. UBS Group reduced their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research note on Tuesday, August 13th. Lifesci Capital downgraded shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. acquired a new stake in ALX Oncology in the second quarter valued at approximately $1,834,000. California State Teachers Retirement System boosted its stake in shares of ALX Oncology by 413.8% during the first quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock worth $254,000 after buying an additional 18,360 shares during the period. Marshall Wace LLP lifted its position in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares during the period. Vanguard Group Inc. lifted its holdings in shares of ALX Oncology by 4.3% during the first quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after purchasing an additional 64,055 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of ALX Oncology in the third quarter valued at about $88,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Stock Up 1.3 %

Shares of NASDAQ ALXO opened at $1.51 on Thursday. The company has a market capitalization of $79.64 million, a P/E ratio of -0.51 and a beta of 1.03. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The company has a 50 day simple moving average of $1.56 and a 200-day simple moving average of $4.64. ALX Oncology has a 1 year low of $1.19 and a 1 year high of $17.83.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.